Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
25.57
USD
|
+0.08%
|
|
+0.12%
|
+58.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,177
|
3,249
|
571.4
|
1,108
|
1,292
|
2,211
|
-
|
-
|
Enterprise Value (EV)
1 |
2,597
|
2,697
|
484.3
|
1,043
|
1,212
|
2,211
|
2,211
|
2,211
|
P/E ratio
|
-13.9
x
|
-11.9
x
|
-1.89
x
|
-6.92
x
|
-7.04
x
|
-12.4
x
|
-15.7
x
|
-37
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
127
x
|
77.2
x
|
5.94
x
|
8.26
x
|
7.91
x
|
10.8
x
|
8.38
x
|
5.9
x
|
EV / Revenue
|
127
x
|
77.2
x
|
5.94
x
|
8.26
x
|
7.91
x
|
10.8
x
|
8.38
x
|
5.9
x
|
EV / EBITDA
|
-15,893,127
x
|
-12,083,939
x
|
-1,923,355
x
|
-6,160,841
x
|
-6,187,870
x
|
-
|
-
|
-
|
EV / FCF
|
-20.6
x
|
-13.3
x
|
-2.35
x
|
-7.21
x
|
-8.76
x
|
-12.6
x
|
-15.2
x
|
-45.1
x
|
FCF Yield
|
-4.85%
|
-7.54%
|
-42.5%
|
-13.9%
|
-11.4%
|
-7.94%
|
-6.57%
|
-2.22%
|
Price to Book
|
5.88
x
|
6.05
x
|
1.88
x
|
3.62
x
|
3.7
x
|
10.1
x
|
8.33
x
|
12.7
x
|
Nbr of stocks (in thousands)
|
51,044
|
56,933
|
58,481
|
67,576
|
80,123
|
86,476
|
-
|
-
|
Reference price
2 |
62.24
|
57.07
|
9.770
|
16.39
|
16.13
|
25.57
|
25.57
|
25.57
|
Announcement Date
|
3/9/20
|
2/9/21
|
2/8/22
|
2/7/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
25
|
42.09
|
96.15
|
134
|
163.4
|
204
|
264
|
375
|
EBITDA
|
-199.9
|
-268.9
|
-297.1
|
-179.8
|
-208.9
|
-
|
-
|
-
|
EBIT
1 |
-200.7
|
-271.2
|
-300.1
|
-182.7
|
-211
|
-194.5
|
-176
|
-111.9
|
Operating Margin
|
-802.9%
|
-644.36%
|
-312.1%
|
-136.32%
|
-129.14%
|
-95.37%
|
-66.68%
|
-29.84%
|
Earnings before Tax (EBT)
1 |
-192.3
|
-266.5
|
-300
|
-178.2
|
-194.5
|
-164.5
|
-147.6
|
-72.71
|
Net income
1 |
-192.3
|
-266.5
|
-300
|
-178.9
|
-194.9
|
-185.5
|
-156
|
-69.84
|
Net margin
|
-769.02%
|
-633.19%
|
-311.98%
|
-133.49%
|
-119.34%
|
-90.93%
|
-59.07%
|
-18.63%
|
EPS
2 |
-4.480
|
-4.780
|
-5.160
|
-2.370
|
-2.290
|
-2.061
|
-1.631
|
-0.6912
|
Free Cash Flow
1 |
-154.2
|
-245
|
-242.8
|
-153.7
|
-147.5
|
-175.6
|
-145.2
|
-49.05
|
FCF margin
|
-616.92%
|
-582.13%
|
-252.52%
|
-114.67%
|
-90.28%
|
-86.09%
|
-55.01%
|
-13.08%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
2/9/21
|
2/8/22
|
2/7/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
24.2
|
29.22
|
32.49
|
35.97
|
36.34
|
33.44
|
38.3
|
43.31
|
48.3
|
45
|
49.6
|
53.7
|
55.04
|
48.29
|
54.3
|
EBITDA
|
-87.62
|
-46.11
|
-42.97
|
-44.14
|
-46.56
|
-52.65
|
-
|
-
|
-50.78
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-88.4
|
-46.89
|
-43.79
|
-44.88
|
-47.16
|
-53.26
|
-52.78
|
-53.69
|
-51.24
|
-48.85
|
-48.76
|
-48.16
|
-47.83
|
-57.29
|
-53.86
|
Operating Margin
|
-365.31%
|
-160.46%
|
-134.76%
|
-124.76%
|
-129.76%
|
-159.24%
|
-137.78%
|
-123.95%
|
-106.09%
|
-108.55%
|
-98.31%
|
-89.68%
|
-86.9%
|
-118.64%
|
-99.19%
|
Earnings before Tax (EBT)
1 |
-88.4
|
-46.89
|
-43.06
|
-43.04
|
-45.23
|
-49.61
|
-48.56
|
-49.58
|
-46.76
|
-45.08
|
-40.08
|
-39.8
|
-39.5
|
-44.11
|
-41.25
|
Net income
1 |
-88.4
|
-46.89
|
-43.06
|
-43.04
|
-45.93
|
-49.61
|
-48.56
|
-49.58
|
-47.19
|
-45.08
|
-46.78
|
-45.26
|
-46.27
|
-48.05
|
-44.62
|
Net margin
|
-365.28%
|
-160.46%
|
-132.52%
|
-119.65%
|
-126.38%
|
-148.33%
|
-126.78%
|
-114.47%
|
-97.71%
|
-100.19%
|
-94.31%
|
-84.28%
|
-84.07%
|
-99.51%
|
-82.18%
|
EPS
2 |
-1.510
|
-0.8000
|
-0.6000
|
-0.5500
|
-0.6000
|
-0.6000
|
-0.5700
|
-0.5800
|
-0.5400
|
-0.5200
|
-0.5312
|
-0.4938
|
-0.5038
|
-0.4950
|
-0.4600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/8/22
|
5/4/22
|
8/4/22
|
11/3/22
|
2/7/23
|
5/3/23
|
8/9/23
|
10/30/23
|
2/6/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
580
|
552
|
87.1
|
64.7
|
80
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-154
|
-245
|
-243
|
-154
|
-147
|
-176
|
-145
|
-49.1
|
ROE (net income / shareholders' equity)
|
-46.5%
|
-48.9%
|
-70.7%
|
-55.4%
|
-56.3%
|
-84%
|
-52%
|
-55%
|
ROA (Net income/ Total Assets)
|
-41%
|
-42.1%
|
-56%
|
-40.5%
|
-42%
|
-
|
-
|
-
|
Assets
1 |
469
|
632.4
|
536
|
441.8
|
463.8
|
-
|
-
|
-
|
Book Value Per Share
2 |
10.60
|
9.440
|
5.200
|
4.530
|
4.360
|
2.530
|
3.070
|
2.020
|
Cash Flow per Share
|
-3.480
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.94
|
5.32
|
1.97
|
0.84
|
0.78
|
2.43
|
2.97
|
3.52
|
Capex / Sales
|
19.74%
|
12.63%
|
2.05%
|
0.63%
|
0.48%
|
1.19%
|
1.13%
|
0.94%
|
Announcement Date
|
3/9/20
|
2/9/21
|
2/8/22
|
2/7/23
|
2/6/24
|
-
|
-
|
-
|
Last Close Price
25.57
USD Average target price
26.71
USD Spread / Average Target +4.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +58.52% | 2.21B | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +2.47% | 22.78B | | -10.53% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|